spacer
home > ict > winter 2019 > concentration-qt modelling in early phase clinical studies
PUBLICATIONS
International Clinical Trials

Concentration-QT Modelling in Early Phase Clinical Studies

Long QT syndrome is a cardiac side effect that can occur with certain pharmaceuticals. After each beat, the heart repolarises, but, with long QT syndrome, this process does not occur correctly. This can lead to a condition known as Torsadede- point arrhythmia, which can cause irregular heartbeats, fainting, and even sudden death, particularly when the patient is under stress or during exercise.

Once it was understood that drugs can cause long QT syndrome, studying cardiac repolarisation became an important part of the drug development process. Regulators now mandate assessment of whether a new drug has a tendency to prolong the QT interval as part of the clinical development process.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Andreas Lindauer has been a Senior Consultant at SGS Exprimo since 2014. He studied pharmacy at the University of Bonn, Germany, subsequently completing a PhD in clinical pharmacy, focussing on PK/ PD modelling in oncology and the central nervous system.
spacer
Dr Andreas Lindauer
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Envigo launches PATHWAY an optimized safety assessment solution to enable first in human clinical trials

11 March 2019, East Millstone, N.J. – Envigo, a leading provider of non-clinical contract research services and research models, announced today the launch of PATHWAY – an integrated solution that optimizes non-clinical safety assessment programs to enable first-in-human clinical trials. PATHWAY is designed to manage the complexity of the entire safety assessment process on behalf of the company’s pharmaceutical and biotechnology customers by integrating safety assessment study types and bioanalytical support with scientific and regulatory consulting, program design and project management.
More info >>

White Papers

Sterile Vials Made of Tubular Glass

Gerresheimer AG

Gx® RTF vials powered by Ompi EZ-fill® enhance flexibility by facilitating packaging needs from clinical stage to industrialization with the common goal to minimize customer product risks and optimize total cost of ownership. Gerresheimer combines the competencies in converting glass tubes to serum/ injection vials and ready-to-fill processing for our pharma and biotech customers.
More info >>

 
Industry Events

World Pharma Week 2019

17-20 June 2019, Seaport World Trade Center, Boston

World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement